Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 176 clinical trials
featured
  • 62 views
  • 23 Nov, 2020
  • 24 locations
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based

  • 1940 views
  • 25 Mar, 2021
  • 107 locations
featured
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with CIT.

non-squamous non-small cell lung cancer
experimental drug
platinum-based chemotherapy
cancer chemotherapy
lung cancer
  • 199 views
  • 24 May, 2021
  • 175 locations
featured
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer.

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non–small

lung carcinoma
non-small cell carcinoma
cancer
platinum-based chemotherapy
cancer chemotherapy
  • 12 views
  • 14 Dec, 2020
  • 1 location
featured
  • 326 views
  • 08 Nov, 2020
  • 27 locations
featured
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (516-003)

following: Whether or not patients were previously treated with or were ineligible for platinum-based chemotherapy  Whether or not patients were previously treated with a

advanced urothelial carcinoma
advanced urothelial cancer
platinum-based chemotherapy
carcinoma
urothelial carcinoma
  • 80 views
  • 02 Jun, 2021
  • 36 locations
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and

  • 84 views
  • 16 Jun, 2021
  • 287 locations
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

-of-care platinum-based chemotherapy and an immune checkpoint inhibitor (ICI). The primary objective is to determine whether SAR408701 improves the overall survival (OS) when compared with

docetaxel
cancer
platinum-based chemotherapy
measurable disease
squamous non-small cell lung cancer
  • 23 views
  • 18 Apr, 2021
  • 218 locations
Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs Niraparib with either Ipilimumab or Nivolumab on patients and their pancreatic cancer.

metastatic pancreatic cancer
ipilimumab
metastasis
cancer
nivolumab
  • 23 views
  • 16 Jun, 2021
  • 1 location
Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

This is a non-randomized, phase-II study of platinum doublet chemotherapy plus ramucirumab in patients with advanced NSCLC who have progressed on first line anti-PD-1 Immunotherapy. Up to 25 evaluable participants will be enrolled over a period of 2 years. Seven patients will be recruited at the first stage .Eligible patients …

pd-1 inhibitor
neutrophil count
platinum-based chemotherapy
cancer chemotherapy
lung carcinoma
  • 1 views
  • 25 Jan, 2021
  • 1 location